Nexmed - Best Pharma Stocks of 2007
Company: Nexmed
Starting stock price: $0.72
Ending stock price: $1.42
Percent Change: 97.22%
Details: Nexmed is using NexACT--it's transdermal drug delivery technology--to create therapies that can be delivered directly through the skin. The company is developing treatments for sexual disorders and nail fungus. In 2007 Nexmed completed patient enrollment in two Phase III studies for it's anti-fungal product, and filed an NDA for an erectile dysfunction treatment.
More News:
NexMed taps Berman as new CEO. Report
More stories about Nexmed
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: